Health Catalyst, Inc. (HCAT) Income Statement

The reported figures suggest revenue growth has decelerated from the low single-digit gains seen through 2024 into outright contraction in the most recent periods. This pattern may indicate that growth depends on a relatively stable customer base rather than meaningful new bookings, and investors should monitor whether the decline persists into subsequent quarters. The data does not disclose the split between volume and pricing or organic and acquired revenue, so the durability of the trend cannot be confirmed from this dataset alone.

The wide quarterly gross margin range suggests cost of revenue is not tracking revenue in a smooth or predictable way, which may reflect implementation cost timing or mix shifts rather than structural pricing power. Compared with DOCS at 89.1 percent, HCAT's gross margin profile appears materially weaker, indicating limited pricing leverage. Investors should monitor whether the 2026Q2 recovery holds, since the dataset does not allow separation of one-time cost items from recurring ones.

Operating leverage has been negative across most periods, as operating losses have not narrowed in line with gross profit movements, suggesting the cost base is not scaling down with revenue. The SG&A and R&D burden appears heavy relative to the gross profit generated, which may indicate the company is still investing ahead of commercial returns. Whether this reflects deliberate investment or structural overhead cannot be determined from the supplied data.

The heavy cost of revenue load suggests delivery and implementation costs are a dominant structural feature of the business. SG&A has stayed elevated relative to revenue, which may reflect the cost of maintaining a sales and administrative infrastructure despite flat top-line results. Management's expense discipline is not clearly evident from the data, as cost lines have not declined consistently alongside revenue.